Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions ...

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

Imagine a gem hunter facing a vast and uncharted landscape to uncover a single beautiful diamond. It is a bit like drug ...

It’s not as much of a stretch as you might think. I’ve always loved bikes. In my early 20s, I was a competitive athlete in ...

With just the click of a button on your smartphone, you can order virtually anything and have it on your doorstep in one or ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...